UCB acquiring Candid Therapeutics for up to $2.2bn
Listed Belgian biopharmaceutical group UCB SA has struck a definitive agreement to acquire clinical-stage biotechnology firm Candid Therapeutics for up to $2.2bn. The deal secures a highly coveted pipeline of novel T-cell engagers for autoimmune diseases. The transaction consists of a $2bn upfront cash payment and up to $200m in potential development milestones. Candid’s lead investigational asset, cizutamig, is a…